85.6000.66% ( +0.560 )
Closed: Nov 13, 16:00:00 (EDT)News
BioNTech falls 4%
Market Movers·BioNTech’s Strong Q3 and Oncology Pipeline Support Buy Rating Despite Price Target Cut to $108
Tip Ranks·- Bank of America Securities analyst Tazeen Ahmad reaffirmed a buy rating on BioNTech while lowering the price target from 114.00 dollars to 108.00 dollars. - The rating is supported by stronger-than-expected third-quarter revenue, an upgraded fiscal year 2026 outlook mid-point, and the commercial potential of its oncology pipeline and pumitamig. - Jefferies also maintained a buy rating on the stock with a price target of 138.00 dollars.BioNTech Q3 2026 Earnings Preview
businessinsider·
